Skip to content

Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00497211
Enrollment
Unknown
Registered
2007-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2007-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

First large acute myocardial infarction

Brief summary

Large acute myocardial infarctions are the most frequent cause of subsequent systolic heart failure. Some evidence exists on the improvement after intracoronary administration of bone marrow cells in patients with a recente acute myocardial infarction. Although subgroup analyses suggest that patients with the largest myocardial infarctions have the largest increase in ejection fraction after intracoronary bone marrow administration, there is no published trial including only large myocardial infarctions. Therefor we sought to confirm the subgroup analyses by conducting a trial in only large first acute myocardial infarction patients.

Interventions

PROCEDUREIntracoronary mononuclear cell infusion

Sponsors

University Hospital, Antwerp
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥20 and \<80 years old * Acute myocardial infarction \>2 and \<96 hours from start to reperfusion * Cumulative ST-segment elevation \>6 mm on 12 lead ECG * No functional myocardial impairment outside the myocardial infarction region * Succesful PCI of infarct related coronary artery * Left ventricular ejection fraction \<50% on ventriculography, echo or MRI * Accepted anticonceptive use during the study for women of childbearing potential * Written and signed informed consent

Exclusion criteria

* CPR \> 10 minuts or persistent cardiogenic shock * complete left bundle branch block without concordant ST-segment elevation * Need foor cardiac surgery (valvular, coronary or other) * Trombocytopenia, coagulation disorders or hematological disease * History or active malignancy * Life expectancy (apart from acute myocardial infarction) \<5 years * Dialysis or severe kidney insufficiency (creatinin clearance \<30ml/') * Severe liver insufficiency * Severe respiratory disease * Systemic inflammatory pathology (acute or chronic, apart from inflammation associated with myocardial infarction) * Symptomatic cerebral or periferal vascular disease * Prior myocardial infarction or prior myocardial dysfunction * Prior CABG or heart valve surgery * Pregnancy, pregnancy wish or lactation \<1 month * Psychiatrical illness * Physical or psychological inability to adhere to the protocol * Participation in other not yet completed study

Countries

Belgium

Contacts

Primary ContactSteven E Haine, MD
steven.haine@uza.be0032.3.821.42.81
Backup ContactMyriam Michiels, Nurse
Myriam.michiels@uza.be0032.3.821.33.04

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026